Natera EBITDA 2014-2025 | NTRA
Natera annual and quarterly EBITDA history from 2014 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Natera EBITDA for the quarter ending March 31, 2025 was $-0.070B, a 3.78% increase year-over-year.
- Natera EBITDA for the twelve months ending March 31, 2025 was $-0.194B, a 45.5% decline year-over-year.
- Natera 2024 annual EBITDA was $-0.191B, a 54.51% decline from 2023.
- Natera 2023 annual EBITDA was $-0.42B, a 19% decline from 2022.
- Natera 2022 annual EBITDA was $-0.518B, a 15.71% increase from 2021.
| Natera Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $-191 |
| 2023 | $-420 |
| 2022 | $-518 |
| 2021 | $-448 |
| 2020 | $-202 |
| 2019 | $-107 |
| 2018 | $-106 |
| 2017 | $-127 |
| 2016 | $-93 |
| 2015 | $-54 |
| 2014 | $6 |
| 2013 | $-23 |
| Natera Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-03-31 | $-70 |
| 2024-12-31 | $-57 |
| 2024-09-30 | $-31 |
| 2024-06-30 | $-36 |
| 2024-03-31 | $-67 |
| 2023-12-31 | $-78 |
| 2023-09-30 | $-103 |
| 2023-06-30 | $-106 |
| 2023-03-31 | $-132 |
| 2022-12-31 | $-137 |
| 2022-09-30 | $-113 |
| 2022-06-30 | $-137 |
| 2022-03-31 | $-132 |
| 2021-12-31 | $-134 |
| 2021-09-30 | $-145 |
| 2021-06-30 | $-111 |
| 2021-03-31 | $-58 |
| 2020-12-31 | $-69 |
| 2020-09-30 | $-54 |
| 2020-06-30 | $-46 |
| 2020-03-31 | $-32 |
| 2019-12-31 | $-32 |
| 2019-09-30 | $-19 |
| 2019-06-30 | $-26 |
| 2019-03-31 | $-30 |
| 2018-12-31 | $-28 |
| 2018-09-30 | $-25 |
| 2018-06-30 | $-25 |
| 2018-03-31 | $-28 |
| 2017-12-31 | $-45 |
| 2017-09-30 | $-24 |
| 2017-06-30 | $-26 |
| 2017-03-31 | $-33 |
| 2016-12-31 | $-40 |
| 2016-09-30 | $-25 |
| 2016-06-30 | $-21 |
| 2016-03-31 | $-8 |
| 2015-12-31 | $-16 |
| 2015-09-30 | $-19 |
| 2015-06-30 | $-14 |
| 2015-03-31 | $-5 |
| 2014-12-31 | |
| 2014-09-30 | $6 |
| 2014-06-30 | $-1 |
| 2013-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $23.347B | $1.697B |
| Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $139.155B | 26.10 |
| Elevance Health (ELV) | United States | $84.931B | 10.96 |
| CVS Health (CVS) | United States | $84.554B | 10.51 |
| Cencora (COR) | United States | $57.517B | 20.01 |
| DiDi Global (DIDIY) | China | $22.403B | 23.80 |
| Labcorp Holdings (LH) | United States | $21.878B | 17.75 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.676B | 0.00 |
| Solventum (SOLV) | United States | $12.566B | 13.30 |
| CochLear (CHEOY) | Australia | $12.083B | 0.00 |
| ICON (ICLR) | Ireland | $11.595B | 10.78 |
| Revvity (RVTY) | United States | $11.128B | 19.15 |
| Doximity (DOCS) | United States | $10.714B | 49.60 |
| Viatris (VTRS) | United States | $10.293B | 3.54 |
| Avantor (AVTR) | United States | $9.056B | 13.16 |
| HealthEquity (HQY) | United States | $8.820B | 38.64 |
| Medpace Holdings (MEDP) | United States | $8.700B | 23.11 |
| Sonic Healthcare (SKHHY) | Australia | $8.407B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.136B | 13.98 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.085B | 24.06 |
| BrightSpring Health Services (BTSG) | United States | $3.934B | 36.10 |
| Sotera Health (SHC) | United States | $3.105B | 17.65 |
| Alignment Healthcare (ALHC) | United States | $2.849B | 0.00 |
| Concentras Parent (CON) | United States | $2.676B | 15.47 |
| Organon (OGN) | United States | $2.568B | 2.73 |
| Surgery Partners (SGRY) | United States | $2.542B | 33.06 |
| PACS (PACS) | United States | $2.027B | 0.00 |
| Progyny (PGNY) | United States | $1.856B | 40.85 |
| Ardent Health (ARDT) | United States | $1.854B | 7.90 |
| GeneDx Holdings (WGS) | United States | $1.838B | 70.80 |
| Premier (PINC) | United States | $1.834B | 13.92 |
| GoodRx Holdings (GDRX) | United States | $1.600B | 32.00 |
| Teladoc Health (TDOC) | United States | $1.230B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.147B | 8.73 |
| Establishment Labs Holdings (ESTA) | $1.100B | 0.00 | |
| CareDx (CDNA) | United States | $1.060B | 16.55 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Agilon Health (AGL) | United States | $0.902B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.856B | 8.01 |
| QDM (QDMI) | Hong Kong, SAR China | $0.758B | 0.00 |
| LifeMD (LFMD) | United States | $0.684B | 0.00 |
| Nutex Health (NUTX) | United States | $0.661B | 10.01 |
| Embecta (EMBC) | United States | $0.569B | 3.83 |
| InnovAge Holding (INNV) | United States | $0.512B | 0.00 |
| SBC Medicals (SBC) | United States | $0.482B | 0.00 |
| Enhabit (EHAB) | United States | $0.473B | 38.92 |
| Auna S.A (AUNA) | Luxembourg | $0.459B | 10.33 |
| Sonida Senior Living (SNDA) | United States | $0.454B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.449B | 0.00 |
| Omada Health (OMDA) | $0.399B | 0.00 | |
| Performant Healthcare (PHLT) | United States | $0.267B | 0.00 |
| Oncology Institute (TOI) | United States | $0.212B | 0.00 |
| Beauty Health (SKIN) | United States | $0.184B | 0.00 |
| DocGo (DCGO) | United States | $0.165B | 27.00 |
| Pheton Holdings (PTHL) | China | $0.119B | 0.00 |
| So-Young (SY) | China | $0.102B | 0.00 |
| KindlyMD (NAKA) | United States | $0.084B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.071B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.059B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.053B | 0.00 |
| ModivCare (MODV) | United States | $0.052B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.049B | 0.00 |
| Biodesix (BDSX) | United States | $0.040B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.034B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.011B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |